@article{28b81d951ab84768a4c41398e67ee5ef,
title = "Applying diagnosis support systems in electronic health records to identify wild-type transthyretin amyloid cardiomyopathy risk",
abstract = "Aim: Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is frequently misdiagnosed, and delayed diagnosis is associated with substantial morbidity and mortality. At three large academic medical centers, combinations of phenotypic features were implemented in electronic health record (EHR) systems to identify patients with heart failure at risk for ATTRwt-CM. Methods: Phenotypes/phenotype combinations were selected based on strength of correlation with ATTRwt-CM versus non-amyloid heart failure; different clinical decision support and reporting approaches and data sources were evaluated on Cerner and Epic EHR platforms. Results: Multiple approaches/sources showed potential usefulness for incorporating predictive analytics into the EHR to identify at-risk patients. Conclusion: These preliminary findings may guide other medical centers in building and implementing similar systems to improve recognition of ATTRwt-CM in patients with heart failure.",
keywords = "amyloidosis, artificial intelligence, cardiomyopathy, diagnosis, electronic health record, heart failure, machine learning, screening, transthyretin",
author = "Connor Willis and Watanabe, {Alexandre H.} and Justin Hughes and Kimberly Nolen and Jason O'meara and Alexander Schepart and Marianna Bruno and Joseph Biskupiak and Kensaku Kawamoto and Nawar Shara and Thomas Kannampallil",
note = "Funding Information: This study was sponsored by Pfizer. Medical writing support was provided by D McGuire of Engage Scientific Solutions and funded by Pfizer. C Willis, A H Watanabe and J Biskupiak have received research grants from Pfizer. J Hughes has no disclosures to report. K Nolen, J O{\textquoteright}Meara, A Schepart and M Bruno are full-time employees of Pfizer and own Pfizer stock and/or stock options. K Kawamoto reports receiving sponsored research grants, writing assistance, consulting fees and honoraria from Pfizer. N Shara has received advisory board honoraria from Pfizer. T Kannampallil has received consulting fees from Pfizer and compensation from Elsevier for serving on editorial boards. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2022 Pfizer.",
year = "2022",
month = may,
doi = "10.2217/fca-2021-0122",
language = "English",
volume = "18",
pages = "367--376",
journal = "Future Cardiology",
issn = "1479-6678",
number = "5",
}